Keyphrases
Airway
11%
Airway Epithelial Cells
7%
Airway Inflammation
7%
Allergen
9%
Allergic Asthma
7%
Allergic Diseases
10%
Allergic Rhinitis
8%
Allergy
10%
American Thoracic Society
5%
Asthma
74%
Asthma Control
8%
Asthma Exacerbation
11%
Asthma Severity
5%
Asthma Symptoms
5%
Atopy
8%
Azithromycin
7%
Body Mass Index
5%
Bronchiolitis Obliterans
7%
Bronchiolitis Obliterans Syndrome
5%
Childhood Asthma
14%
Children with Asthma
10%
Cilia
5%
Clinical Outcomes
5%
Clinical Trials
11%
Confidence Interval
8%
COVID-19
7%
Cystic Fibrosis
100%
Cystic Fibrosis Foundation
5%
Cystic Fibrosis Lung Disease
7%
Cystic Fibrosis Transmembrane Conductance Regulator
19%
Early childhood
5%
Epithelial Cells
5%
Epithelial Sodium Channel (ENaC)
11%
Fluticasone Propionate
7%
Forced Expiratory Volume in 1 Second (FEV1)
17%
Gene Transfer
8%
Genotype
7%
Heart-lung
5%
High Risk
8%
Inflammation
6%
Inhaled Corticosteroids
20%
Ivacaftor
5%
Lung
16%
Lung Disease
5%
Lung Function
16%
Lung Transplantation
42%
Moderate to Severe
5%
Omalizumab
5%
Oral Corticosteroids
5%
Pancreatic Insufficient
6%
Pediatric
20%
Pediatric Asthma
10%
Pediatric Lung Transplantation
27%
Pediatric Patients
9%
Persistent Asthma
6%
Placebo
11%
Post-transplant Lymphoproliferative Disorder
5%
Prematurity
5%
Preschool children
19%
Primary Ciliary Dyskinesia
32%
Pseudomonas Aeruginosa (P. aeruginosa)
7%
Pulmonary Function
8%
Rebreathing
5%
Recurrent Wheeze
6%
Recurrent Wheezing
8%
Respiratory Outcomes
5%
Respiratory Syncytial Virus
5%
Risk Factors
9%
Severe Asthma
10%
Severe Asthma Research Program
5%
Sublingual Immunotherapy
5%
Sudden Infant Death Syndrome
6%
Transplantation
11%
United States
11%
Virus
6%
Vitamin D
7%
Wheezing
15%
Young children
9%
Medicine and Dentistry
Adolescence
11%
Asthma
54%
Azithromycin
5%
Breathing
9%
Bronchiolitis Obliterans
10%
Clinical Trial
9%
COVID-19
5%
Cystic Fibrosis
78%
Cystic Fibrosis Transmembrane Conductance Regulator
8%
Diagnosis
6%
Diseases
23%
Forced Expiratory Volume
9%
Glucose Tolerance
6%
Infection
11%
Ivacaftor
7%
Lung
45%
Lung Function
5%
Lung Transplantation
51%
Nitric Oxide
5%
Patient with Cystic Fibrosis
12%
Pediatrics
58%
Pediatrics Patient
6%
Placebo
12%
Prematurity
7%
Preschooler
11%
Primary Ciliary Dyskinesia
19%
Pseudomonas aeruginosa
6%
Pulmonary Hypertension
5%
Rebreathing
5%
Respiratory Disease
7%
Sensitization
5%
Silo-Filler's Disease
15%
Sudden Infant Death Syndrome
8%
Systematic Review
5%
Tezacaftor
5%
Toddlers
6%
Transplantation
19%
Vitamin D
5%
Wheeze
17%